GSDMD and prostate adenocarcinoma: Third, tumor-type-specific immune landscapes likely contribute: PRAD and MESO typically exhibit higher immunocyte infiltration, where GSDMD-driven pyroptosis may synergize with anti-tumor immunity, whereas ACC/LGG’s immunosuppressive niches might convert pyroptotic debris into pro-metastatic signals.